Zurich, Switzerland
MaxWell Biosystems, founded in 2016 as an ETH Zürich spin-off, has positioned itself as a pioneering force in the fields of Biotechnology and Health Care. Operating out of Switzerland, this company leverages state-of-the-art technology to enhance research and development across various domains, including neuroscience, stem cell and tissue engineering, and ophthalmology.
With its flagship products, MaxOne and MaxTwo, MaxWell Biosystems advances the precision and efficacy of scientific exploration by enabling detailed recording of neuronal electrical activity in 2D and 3D in-vitro models. These systems empower scientists to monitor neuronal activity at network, cellular, and subcellular levels, thereby accelerating breakthroughs in scientific research and drug discovery.
The company's commitment to innovation and partnership made it an attractive investment opportunity, as evidenced by its latest Debt Financing investment from the Technology Fund on December 10, 2021. As it continues to expand its offerings, MaxWell Biosystems remains dedicated to driving advancements in biomedical sciences and providing trusted solutions to its users and collaborators.
Curi Bio